Can SIBO cause fatty liver? Small intestinal bacterial overgrowth (SIBO) and non-alcoholic fatty liver disease (NAFLD) are increasingly recognised conditions that may share common metabolic risk factors. Whilst emerging research has identified associations between gut bacterial imbalance and liver fat accumulation, it is important to understand that no established causal link has been proven. This article examines the current evidence on the relationship between SIBO and fatty liver disease, explores proposed biological mechanisms, and provides guidance on diagnosis and management approaches aligned with UK clinical practice and NICE recommendations.

Understanding SIBO and Fatty Liver Disease

Small intestinal bacterial overgrowth (SIBO) is a condition characterised by an abnormal increase in the number of bacteria in the small intestine, or a change in the types of bacteria present. Normally, the small intestine contains relatively few bacteria compared to the large intestine. When this balance is disrupted, patients may experience bloating, abdominal pain, diarrhoea, and malabsorption of nutrients. SIBO can arise from various underlying conditions, including structural abnormalities, motility disorders, or conditions that reduce gastric acid production.

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver conditions characterised by excessive fat accumulation in the liver (hepatic steatosis) in individuals who consume little to no alcohol. NAFLD affects approximately 20–30% of the general population in the UK and is closely associated with metabolic syndrome, obesity, type 2 diabetes, and dyslipidaemia. The condition can progress from simple steatosis to non-alcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, and hepatocellular carcinoma.

Both conditions represent significant public health concerns and share common risk factors, particularly metabolic dysfunction. Understanding the potential relationship between gut bacterial imbalance and liver disease has become an area of increasing research interest. The gut-liver axis—the bidirectional communication between the gastrointestinal tract and the liver—plays a crucial role in maintaining metabolic homeostasis. Disruption of this axis through bacterial overgrowth may have implications for liver health, though the precise mechanisms and clinical significance continue to be investigated.

It is important to note that routine population screening for NAFLD is not recommended. According to NICE guidance (NG49), assessment focuses on individuals with risk factors such as obesity, type 2 diabetes, or metabolic syndrome, rather than the general population.

The Link Between SIBO and Fatty Liver: What Research Shows

Emerging research suggests a potential association between SIBO and NAFLD, though it is important to emphasise that there is no established causal link between SIBO and fatty liver disease. Several observational studies have reported a higher prevalence of SIBO in patients with NAFLD compared to healthy controls, with some studies indicating prevalence rates ranging from 30% to over 70% in NAFLD populations. However, these findings should be interpreted cautiously, as correlation does not establish causation, and the studies used heterogeneous diagnostic criteria and testing methods for SIBO.

A systematic review and meta-analysis examining the relationship between SIBO and NAFLD found a statistically significant association between the two conditions. The pooled data suggested that patients with NAFLD were more likely to test positive for SIBO using breath testing compared to control groups. However, the quality of evidence varied across studies, and many were limited by small sample sizes, variable definitions of SIBO, and potential confounding factors such as obesity and diabetes. It is also important to note that breath test positivity for methane relates to intestinal methanogen overgrowth (IMO) rather than classic SIBO, representing a distinct condition.

The proposed mechanisms linking these conditions involve alterations in gut permeability, bacterial translocation, and metabolic endotoxaemia. When the intestinal barrier function is compromised—more precisely termed increased intestinal permeability—bacterial products such as lipopolysaccharide (LPS) may enter the portal circulation and reach the liver. This can trigger inflammatory responses and metabolic disturbances that may contribute to hepatic fat accumulation.

Despite these intriguing findings, current evidence does not support a definitive causal relationship, and current UK guidance does not recommend routine SIBO testing in patients with NAFLD. The association may be bidirectional, with liver disease potentially predisposing to SIBO through altered bile acid metabolism and intestinal motility. Further prospective studies and randomised controlled trials are needed to clarify whether treating SIBO can improve liver outcomes in patients with NAFLD.

How SIBO May Contribute to Liver Fat Accumulation

Several biological mechanisms have been proposed to explain how SIBO might theoretically contribute to the development or progression of fatty liver disease. It is important to emphasise that these mechanisms remain hypothetical and are not proven causal pathways in humans; they represent areas of active investigation rather than established clinical facts.

Increased intestinal permeability and endotoxaemia represent a key proposed mechanism. Bacterial overgrowth may compromise the integrity of the intestinal epithelial barrier, allowing bacterial products—particularly lipopolysaccharide from Gram-negative bacteria—to translocate into the portal circulation. Upon reaching the liver, LPS binds to Toll-like receptor 4 (TLR4) on hepatocytes and Kupffer cells, triggering inflammatory cascades involving nuclear factor-kappa B (NF-κB) and the production of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). This chronic low-grade inflammation may promote insulin resistance and dysregulate lipid metabolism, favouring hepatic fat accumulation.

Altered bile acid metabolism may also play a role. Bacteria in the small intestine can deconjugate bile acids prematurely, reducing their ability to facilitate fat absorption and potentially disrupting the enterohepatic circulation. Bile acids also function as signalling molecules through the farnesoid X receptor (FXR), which regulates glucose and lipid metabolism. Dysregulation of bile acid signalling may contribute to metabolic dysfunction and hepatic steatosis.

Production of toxic metabolites by overgrown bacteria has been proposed as another mechanism. Some bacterial species can ferment carbohydrates to produce substances including ethanol and acetaldehyde, which are then absorbed and metabolised by the liver. Whilst this endogenous alcohol production has been hypothesised to contribute to liver fat accumulation, the quantities produced in SIBO are generally much lower than those from exogenous alcohol consumption, and the clinical significance remains uncertain. Additionally, SIBO may impair nutrient absorption, potentially leading to deficiencies in nutrients such as choline that are important for hepatic lipid export, though this mechanism also requires further validation in clinical studies.

Symptoms That May Indicate Both SIBO and Fatty Liver

Recognising the clinical presentations of SIBO and fatty liver disease can be challenging, as both conditions may be asymptomatic or present with non-specific symptoms. Understanding the typical manifestations of each condition can help patients and healthcare professionals identify when further investigation may be warranted.

SIBO typically presents with gastrointestinal symptoms, including:

• Bloating and abdominal distension, often worsening throughout the day or after meals

• Abdominal pain or discomfort, which may be cramping in nature

• Diarrhoea, sometimes alternating with constipation

• Excessive flatulence

• Malabsorption symptoms, such as steatorrhoea (fatty stools), weight loss, or nutritional deficiencies (particularly fat-soluble vitamins A, D, E, and K, and vitamin B12)

Fatty liver disease, particularly in its early stages, is often asymptomatic. When symptoms do occur, they may include:

• Fatigue and general malaise

• Vague right upper quadrant discomfort or a sensation of fullness

• In more advanced disease (NASH or fibrosis), patients may develop signs of chronic liver disease

Patients with both conditions might experience a combination of digestive symptoms and non-specific systemic complaints such as fatigue. However, the presence of gastrointestinal symptoms does not indicate liver involvement, and conversely, fatty liver disease can exist without any digestive complaints. Many patients with NAFLD are diagnosed incidentally through abnormal liver function tests or imaging performed for other reasons.

When to seek urgent medical attention: Patients should seek same-day or emergency assessment if they experience:

• Jaundice (yellowing of the skin or eyes)

• Gastrointestinal bleeding (vomiting blood or passing black, tarry stools)

• Confusion or altered mental state (possible hepatic encephalopathy)

• Fever with right upper quadrant pain

• Rapidly increasing abdominal swelling (ascites) or leg swelling (oedema)

• Severe unintentional weight loss

When to consult your GP: Patients experiencing persistent digestive symptoms, unexplained weight loss, signs of malabsorption, or persistently abnormal liver function tests should consult their GP. Anyone with risk factors for fatty liver disease (obesity, diabetes, metabolic syndrome) should discuss appropriate assessment with their GP. If advanced liver fibrosis is suspected based on risk stratification scores or blood tests, your GP will arrange referral to secondary care hepatology services.

Diagnosis and Testing for SIBO and Fatty Liver Disease

Accurate diagnosis of both SIBO and fatty liver disease requires specific investigations, as clinical symptoms alone are insufficient for definitive diagnosis.

SIBO diagnosis primarily relies on:

• Breath testing: The most commonly used non-invasive diagnostic method involves measuring hydrogen and methane levels in breath samples after ingestion of a substrate (either glucose or lactulose). For glucose breath testing, an early rise in hydrogen (≥20 ppm above baseline within 90 minutes) suggests SIBO. For lactulose testing, a rise within 90 minutes may indicate SIBO, though interpretation is more complex. Elevated methane levels (≥10 ppm at any point) indicate intestinal methanogen overgrowth (IMO) rather than classic SIBO, representing a distinct condition. Breath testing has limitations, including variable sensitivity and specificity, and results should be interpreted in clinical context alongside symptoms.

• Small bowel aspirate and culture: This involves endoscopic aspiration of small intestinal fluid with quantitative bacterial culture. A count of ≥10³ colony-forming units per millilitre has traditionally been considered diagnostic, though this threshold and the method itself have practical limitations, including risk of contamination and sampling variability. The procedure is invasive, expensive, and not widely available in routine UK practice.

• Empirical treatment trial: In some cases, clinicians may consider a therapeutic trial of antibiotics if clinical suspicion is high and testing is unavailable, inconclusive, or impractical.

Fatty liver disease diagnosis involves:

• Liver function tests (LFTs): Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may indicate liver inflammation, though normal LFTs do not exclude NAFLD. Persistently abnormal LFTs warrant further investigation according to British Society of Gastroenterology guidance.

• Imaging studies: Ultrasound is the first-line imaging modality and can detect moderate to severe steatosis, though it is important to note that a normal ultrasound does not exclude NAFLD, particularly when steatosis is mild. More advanced techniques include controlled attenuation parameter (CAP) via transient elastography (FibroScan), CT, or MRI, which can quantify liver fat more precisely.

• Non-invasive fibrosis assessment: According to NICE NG49 guidance, patients with suspected NAFLD should undergo risk stratification using validated scores. The recommended pathway is:

• First-line: Calculate FIB-4 score or NAFLD Fibrosis Score (NFS). These scores use age, liver enzymes, platelet count, and other readily available parameters. Age-specific cut-offs apply, as FIB-4 may overestimate fibrosis risk in older patients and underestimate it in younger patients.
• Second-line: If the initial score suggests intermediate or high risk of advanced fibrosis, proceed to the Enhanced Liver Fibrosis (ELF) blood test. An ELF score of ≥10.51 suggests advanced fibrosis and warrants referral to hepatology services.

• FibroScan (transient elastography) measures liver stiffness and can also assess fibrosis stage, often used in secondary care.

• Liver biopsy: Reserved for cases where the diagnosis is uncertain or to assess disease severity, particularly when NASH or advanced fibrosis is suspected and non-invasive tests are inconclusive.

According to NICE NG49 guidance, patients with suspected NAFLD should undergo comprehensive metabolic assessment, including fasting glucose or HbA1c, lipid profile, and assessment for metabolic syndrome components. Both conditions require exclusion of alternative diagnoses—other causes of liver disease (viral hepatitis, alcohol-related liver disease, haemochromatosis, autoimmune hepatitis) for NAFLD, and structural or motility disorders for SIBO.

Treatment Approaches: Managing SIBO to Support Liver Health

Management of SIBO and fatty liver disease requires individualised approaches, and whilst treating SIBO may theoretically benefit liver health, there is currently insufficient evidence to confirm that SIBO treatment directly improves fatty liver disease outcomes.

SIBO treatment typically involves:

• Antibiotic therapy: Rifaximin is commonly used due to its minimal systemic absorption and broad-spectrum activity against enteric bacteria. It is important to note that rifaximin is not licensed for SIBO in the UK; its use for this indication is off-label and should only be undertaken under specialist supervision after appropriate assessment. Typical courses last 10–14 days. Alternative antibiotics include metronidazole or, in selected cases, ciprofloxacin. However, the MHRA has issued important restrictions on fluoroquinolone antibiotics (including ciprofloxacin) due to risks of disabling and potentially long-lasting or irreversible side effects. Ciprofloxacin should be reserved for situations where the benefits clearly outweigh the risks and when other suitable alternatives are not available. All antibiotic use should follow antimicrobial stewardship principles, and patients should be aware of the risk of Clostridioides difficile infection with any antibiotic course. Treatment success rates vary, and recurrence is common, particularly if underlying predisposing factors are not addressed.

• Addressing underlying causes: Identifying and managing conditions that predispose to SIBO—such as intestinal dysmotility, structural abnormalities, or reduced gastric acid production—is essential for long-term management.

• Dietary modifications: Some patients benefit from a low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet, which reduces fermentable substrates for bacteria. However, this should be undertaken with dietetic supervision to prevent nutritional deficiencies and to ensure appropriate reintroduction phases.

• Prokinetic agents: In selected cases with documented motility disorders, prokinetic medications may help prevent bacterial overgrowth recurrence. However, their use in the UK is limited, and some agents carry cardiac risks (including QT prolongation); specialist advice is recommended.

Fatty liver disease management, according to NICE NG49 guidance, focuses on:

• Lifestyle modification: Weight loss of 7–10% of body weight through caloric restriction and increased physical activity is the cornerstone of NAFLD treatment and can significantly reduce liver fat and inflammation. Structured weight-loss programmes with dietetic support are recommended. Patients should also follow UK Chief Medical Officers' low-risk alcohol guidance (no more than 14 units per week, spread over at least three days, with several alcohol-free days).

• Management of metabolic comorbidities: Optimising control of type 2 diabetes, hypertension, and dyslipidaemia is essential and may improve liver outcomes.

• Pharmacological interventions: Currently, no medications are specifically licensed for NAFLD or NASH in the UK. Vitamin E and pioglitazone may be considered off-label in specialist care for patients with biopsy-proven NASH. Vitamin E is generally reserved for non-diabetic patients, whilst pioglitazone may be used in selected patients with or without diabetes, after discussion of risks and benefits. These treatments should only be initiated by specialists with expertise in liver disease. Pioglitazone carries risks including weight gain, fluid retention, heart failure, bone fractures, and bladder cancer; vitamin E at high doses may increase cardiovascular and other risks. Patients prescribed these medicines should be counselled about potential side effects.

• Avoidance of hepatotoxins: Patients should limit alcohol consumption as above and review medications that may affect the liver with their GP or pharmacist.

Integrated approach: For patients with both conditions, a comprehensive strategy addressing metabolic health, gut microbiome balance, and underlying gastrointestinal disorders is advisable. Patients should work closely with their GP and, where appropriate, specialists in gastroenterology and hepatology. Regular monitoring of liver function and metabolic parameters is important. If symptoms persist despite treatment, if there are signs of progressive liver disease, or if fibrosis risk scores indicate advanced fibrosis, prompt referral to secondary care is warranted.

Reporting side effects: If you experience any suspected side effects from medicines used to treat SIBO or fatty liver disease, you can report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or by searching for 'Yellow Card' in the Google Play or Apple App Store.

Frequently Asked Questions